HST9 Inotersen for treating hereditary transthyretin amyloidosis 1 Recommendations 1.1 Inotersen is recommended
HST10 Patisiran for treating hereditary transthyretin amyloidosis 1 Recommendations 1.1 Patisiran
Everything NICE has said on endocrine, nutritional and metabolic conditions in an interactive flowchart
Ashutosh Wechalekar MD, FRCP, FRCPath, DM, NHS representative UK National Amyloidosis Centre, Department of Medicine, University College...
The complete list of highly specialised technologies guidance published by NICE.
treating hereditary transthyretin-related amyloidosis. Patisiran for treating hereditary transthyretin-related amyloidosis....
Proposed [GID-TA10451] Expected publication date: 10 June 2020
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making